ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Account Payables

Amounts the company owes suppliers for goods and services received.

ProQR Therapeutics N.V.NASDAQ: PRQR

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables falls 57.7% from a year ago

Account payables stood at €189.2K at the end of Q1 FY2026, down 57.7% from a year earlier and down 36.5% from the prior quarter. Over 3 fiscal years it compounded at -8.7% a year.

Context

  • Account payables amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -57.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
€189.2K-36.5% QoQ
Last fiscal yearDec 2025
€297.87K+1761.7% YoY
Year agoMar 2025
€447.2K-57.7% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.7%——
1 year+1761.7%——
3-year CAGR-8.7%——
5-year CAGR——
10-year CAGR——

Account Payables history

EUR · from the balance sheet

Latest · FY2025
297.87K EUR
Year-over-year change
+1761.7%
4-year CAGR
+11.8%

Account Payables vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -57.7% is the lowest of 11, against a peer median of -11.6%.
  • Account payables amounts to 0.2% of total assets for PRQR, versus a peer median of 1.5%.
PRQR Competitors
Account Payables for PRQR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMMPImmutep LimitedDec 2025A$9.03M AUD+126.7%+24.5%6.1%
ALLOAllogene Therapeutics, Inc.Mar 2026$4.93M USD-2.5%-32.5%1.2%
VNDAVanda Pharmaceuticals Inc.Mar 2026$4.47M USD-25.3%-27.0%1.0%
EDITEditas Medicine, Inc.Mar 2026$4.33M USD-20.7%-35.1%2.9%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$4.09M USD-33.8%-17.2%1.7%
CAPRCapricor Therapeutics, Inc.Mar 2026$3.93M USD-25.2%-30.0%1.2%
MREOMereo BioPharma Group plcMar 2026$3.23M USD+10.3%-27.5%7.9%
TRDAEntrada Therapeutics, Inc.Mar 2026$2.93M USD+33.9%-27.4%0.9%
ZURAZura Bio LimitedMar 2026$2.08M USD+66.8%-14.0%0.9%
ACHVAchieve Life Sciences, Inc.Mar 2026$833K USD-49.7%-19.5%2.5%
PRQRProQR Therapeutics N.V.Mar 2026€189.2K EUR-57.7%-8.7%0.2%
Peer median (excluding PRQR) —-11.6%-27.2%1.5%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents187.52M94.78M131.37M149.41M92.37M
Short-term Investments00000
Net Receivables823K56.25M1.4M2.03M5.08M
Inventory00000
Other Current Assets823K982K02.03M0
Total Current Assets191.48M154.46M133.65M153.85M100.08M
Property, Plant & Equipment (Net)17.47M16.24M18.67M14.11M12.62M
Goodwill00000
Intangible Assets00000
Long-term Investments629K621K000
Tax Assets00000
Other Non-current Assets01000
Total Non-current Assets18.1M16.86M18.67M14.11M12.62M
Total Assets209.58M171.32M152.31M167.96M112.71M
Account Payables191K392K1.7M16K297.87K
Short-term Debt4.77M2.5M1.78M4.58M4.44M
Tax Payables00000
Deferred Revenue0022.72M017.54M
Other Current Liabilities19.87M15.59M11.58M31.26M10.14M
Total Current Liabilities27.6M20.99M37.78M38.9M32.43M
Long-term Debt39.32M4.27M4.74M00
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0048.79M021.38M
Other Non-current Liabilities14.69M65.57M029.43M0
Total Non-current Liabilities68.75M83.65M68.81M40.5M30.93M
Total Liabilities96.35M104.64M106.59M79.4M63.36M
Common Stock3M3.37M3.72M4.31M4.31M
Retained Earnings(317.77M)(379.11M)(442.8M)(427.16M)(467.31M)
Accumulated OCI30.3M30.26M28.69M27.6M28.68M
Other Stockholders Equity11000
Minority Interest(604K)(384K)000
Total Equity113.23M66.68M45.72M88.56M49.35M
Total Debt60.37M21.97M21.8M17.22M13.99M
Net Debt(127.15M)(72.8M)(109.57M)(132.19M)(78.39M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.